-
Posted: March 11th, 2010, 10:00pm CST
The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced the publication of results from a clinical phase II trial evaluating the company's liver selective thyroid hormone receptor agonist eprotirome and its ability to further reduce serum LDL cholesterol levels in statin-treated patients...
-
Posted: March 11th, 2010, 5:00am CST
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published in the New England Journal of Medicine. "Our study has shown a dramatic reduction in the dangerous fats that cause heart disease, the number one killer of Americans," said Dr...
-
Posted: March 11th, 2010, 5:00am CST
People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar...
-
Posted: March 11th, 2010, 4:00am CST
Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers...